Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In a report released today, Jason Bednar from Piper Sandler maintained a Buy rating on Becton Dickinson (BDX – Research Report), with a price ...

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) had its target price hoisted by analysts at Piper Sandler from $275.00 to $280.00 in a research report issued on Tuesday,Benzinga reports.

Piper Sandler raised the firm’s price target on Becton Dickinson (BDX) to $280 from $275 and keeps an Overweight rating on the shares. The firm ...

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) announced that its board has authorized a share buyback program on ...

Becton, Dickinson and Company (NYSE:BDX), a leading player in the medical technology sector with a market capitalization of ...

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Becton, Dickinson and Company (NYSE:BDX), a leading player in the medical technology sector with a market capitalization of $70.53 billion, has been the subject of intense scrutiny by financial ...

Piper Sandler's analysts increased the price target for Becton Dickinson (NYSE:BDX) shares to $280 from $275, while ...